The Use of Viral Vectors to Promote Repair After Spinal Cord Injury

Overview

Journal Exp Neurol

Specialty Neurology

Date 2022 May 5

PMID 35513025

Authors

Ashraful Islam

Veronica J Tom

Affiliations

Soon will be listed here.

Abstract

Spinal cord injury (SCI) is a devastating event that can permanently disrupt multiple modalities. Unfortunately, the combination of the inhibitory environment at a central nervous system (CNS) injury site and the diminished intrinsic capacity of adult axons for growth results in the failure for robust axonal regeneration, limiting the ability for repair. Delivering genetic material that can either positively or negatively modulate gene expression has the potential to counter the obstacles that hinder axon growth within the spinal cord after injury. A popular gene therapy method is to deliver the genetic material using viral vectors. There are considerations when deciding on a viral vector approach for a particular application, including the type of vector, as well as serotypes, and promoters. In this review, we will discuss some of the aspects to consider when utilizing a viral vector approach to as a therapy for SCI. Additionally, we will discuss some recent applications of gene therapy to target extrinsic and/or intrinsic barriers to promote axon regeneration after SCI in preclinical models. While still in early stages, this approach has potential to treat those living with SCI.

Citing Articles

Modulation of pain sensitivity by Ascl1- and Lhx6-dependent GABAergic neuronal function in streptozotocin diabetic mice.

Hwang S, Rahman M, Go E, Roh J, Park R, Lee S Mol Ther. 2025; 33(2):786-804.

PMID: 39741412 PMC: 11852955. DOI: 10.1016/j.ymthe.2024.12.039.

Revisiting the Emerging Role of Light-Based Therapies in the Management of Spinal Cord Injuries.

Sen S, Parihar N, Patil P, Upadhyayula S, Pemmaraju D Mol Neurobiol. 2024; .

PMID: 39658774 DOI: 10.1007/s12035-024-04658-8.

Designing molecules: directing stem cell differentiation.

Thanaskody K, Natashah F, Nordin F, Wan Kamarul Zaman W, Tye G Front Bioeng Biotechnol. 2024; 12:1396405.

PMID: 38803845 PMC: 11129639. DOI: 10.3389/fbioe.2024.1396405.

Redifferentiation of genetically modified dedifferentiated chondrocytes in a microcavitary hydrogel.

Yao Y, Chen K, Pan Q, Gao H, Su W, Zheng S Biotechnol Lett. 2024; 46(3):483-495.

PMID: 38523201 DOI: 10.1007/s10529-024-03475-2.

Schwann Cell-Derived Exosomal Vesicles: A Promising Therapy for the Injured Spinal Cord.

Ghosh M, Pearse D Int J Mol Sci. 2023; 24(24.

PMID: 38139147 PMC: 10743801. DOI: 10.3390/ijms242417317.

References

Snyder B, Gray S, Quach E, Huang J, Leung C, Samulski R . Comparison of adeno-associated viral vector serotypes for spinal cord and motor neuron gene delivery. Hum Gene Ther. 2011; 22(9):1129-35. DOI: 10.1089/hum.2011.008. View

OCarroll S, Cook W, Young D . AAV Targeting of Glial Cell Types in the Central and Peripheral Nervous System and Relevance to Human Gene Therapy. Front Mol Neurosci. 2021; 13:618020. PMC: 7829478. DOI: 10.3389/fnmol.2020.618020. View

Pignataro D, Sucunza D, Vanrell L, Lopez-Franco E, Dopeso-Reyes I, Vales A . Adeno-Associated Viral Vectors Serotype 8 for Cell-Specific Delivery of Therapeutic Genes in the Central Nervous System. Front Neuroanat. 2017; 11:2. PMC: 5301009. DOI: 10.3389/fnana.2017.00002. View

Hordeaux J, Buza E, Jeffrey B, Song C, Jahan T, Yuan Y . MicroRNA-mediated inhibition of transgene expression reduces dorsal root ganglion toxicity by AAV vectors in primates. Sci Transl Med. 2020; 12(569). DOI: 10.1126/scitranslmed.aba9188. View

Danilov C, Steward O . Conditional genetic deletion of PTEN after a spinal cord injury enhances regenerative growth of CST axons and motor function recovery in mice. Exp Neurol. 2015; 266:147-60. PMC: 4382431. DOI: 10.1016/j.expneurol.2015.02.012. View

Hardcastle N, Boulis N, Federici T . AAV gene delivery to the spinal cord: serotypes, methods, candidate diseases, and clinical trials. Expert Opin Biol Ther. 2017; 18(3):293-307. DOI: 10.1080/14712598.2018.1416089. View

Sondhi D, Hackett N, Peterson D, Stratton J, Baad M, Travis K . Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector. Mol Ther. 2006; 15(3):481-91. DOI: 10.1038/sj.mt.6300049. View

Silva N, Sousa N, Reis R, Salgado A . From basics to clinical: a comprehensive review on spinal cord injury. Prog Neurobiol. 2013; 114:25-57. DOI: 10.1016/j.pneurobio.2013.11.002. View

Wold W, Toth K . Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther. 2013; 13(6):421-33. PMC: 4507798. DOI: 10.2174/1566523213666131125095046. View

10.

Blackmore M, Wang Z, Lerch J, Motti D, Zhang Y, Shields C . Krüppel-like Factor 7 engineered for transcriptional activation promotes axon regeneration in the adult corticospinal tract. Proc Natl Acad Sci U S A. 2012; 109(19):7517-22. PMC: 3358880. DOI: 10.1073/pnas.1120684109. View

11.

Park K, Liu K, Hu Y, Kanter J, He Z . PTEN/mTOR and axon regeneration. Exp Neurol. 2010; 223(1):45-50. DOI: 10.1016/j.expneurol.2009.12.032. View

12.

Hoyng S, Gnavi S, De Winter F, Eggers R, Ozawa T, Zaldumbide A . Developing a potentially immunologically inert tetracycline-regulatable viral vector for gene therapy in the peripheral nerve. Gene Ther. 2014; 21(6):549-57. DOI: 10.1038/gt.2014.22. View

13.

Su Z, Niu W, Liu M, Zou Y, Zhang C . In vivo conversion of astrocytes to neurons in the injured adult spinal cord. Nat Commun. 2014; 5:3338. PMC: 3966078. DOI: 10.1038/ncomms4338. View

14.

Gallent E, Steward O . Neuronal PTEN deletion in adult cortical neurons triggers progressive growth of cell bodies, dendrites, and axons. Exp Neurol. 2018; 303:12-28. PMC: 5864555. DOI: 10.1016/j.expneurol.2018.01.005. View

15.

Burnside E, de Winter F, Didangelos A, James N, Andreica E, Layard-Horsfall H . Immune-evasive gene switch enables regulated delivery of chondroitinase after spinal cord injury. Brain. 2018; 141(8):2362-2381. PMC: 6061881. DOI: 10.1093/brain/awy158. View

16.

Fagoe N, Attwell C, Kouwenhoven D, Verhaagen J, Mason M . Overexpression of ATF3 or the combination of ATF3, c-Jun, STAT3 and Smad1 promotes regeneration of the central axon branch of sensory neurons but without synergistic effects. Hum Mol Genet. 2015; 24(23):6788-800. DOI: 10.1093/hmg/ddv383. View

17.

Chen Y, Ma N, Pei Z, Wu Z, Do-Monte F, Keefe S . A NeuroD1 AAV-Based Gene Therapy for Functional Brain Repair after Ischemic Injury through In Vivo Astrocyte-to-Neuron Conversion. Mol Ther. 2019; 28(1):217-234. PMC: 6952185. DOI: 10.1016/j.ymthe.2019.09.003. View

18.

Romero M, Rangappa N, Li L, Lightfoot E, Garry M, Smith G . Extensive sprouting of sensory afferents and hyperalgesia induced by conditional expression of nerve growth factor in the adult spinal cord. J Neurosci. 2000; 20(12):4435-45. PMC: 6772437. View

19.

Besnard F, Brenner M, Nakatani Y, Chao R, Purohit H, Freese E . Multiple interacting sites regulate astrocyte-specific transcription of the human gene for glial fibrillary acidic protein. J Biol Chem. 1991; 266(28):18877-83. View

20.

Uchida K, Nakajima H, Hirai T, Yayama T, Chen K, Guerrero A . The retrograde delivery of adenovirus vector carrying the gene for brain-derived neurotrophic factor protects neurons and oligodendrocytes from apoptosis in the chronically compressed spinal cord of twy/twy mice. Spine (Phila Pa 1976). 2012; 37(26):2125-35. DOI: 10.1097/BRS.0b013e3182600ef7. View